Author

L. D. Boila

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Approach:mechanistic / dynamical model· 1

Frequent Co-Authors

A. Arruda· 1 shared A. Bose· 1 shared A. G. X. Zeng· 1 shared A. Mitchell· 1 shared A. Murison· 1 shared A. Sengupta· 1 shared D. Banerjee· 1 shared E. R. Lechman· 1 shared

Activity by Year

2022-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Arruda

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

KDM6A loss sensitizes human acute myeloid leukemia to PARP and BCL2 inhibition

L. D. Boila, S. Ghosh, S. K. Bandyopadhyay, L. Jin, A. Murison, A. G. X. Zeng, W. Shaikh, S. Bhowmik, S. S. N. A. Muddineni, M. Biswas, S. Sinha, S. S. Chatterjee, N. Mbong, O. I. Gan, A. Bose, , A. Sengupta

This study shows that KDM6A loss in AML increases sensitivity to PARP and BCL2 inhibitors, suggesting a new combination therapy approach for KDM6A-mutant AML.

bioRxiv · Jul 12, 2022 · PreprintCancer Biology